SciClone Pharmaceuticals, Inc. (SCLN)

Check out top investors' recommendation for SCLN
Last closing price (Feb 25 4:00 EDT):
7.70 (0.26%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
-9.73% ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
SciClone Pharmaceuticals, Inc. provides therapies for the treatment of oncology, infectious diseases, cardiovascular, urological, respiratory, and central nervous system disorders in the People’s Republic of China and internationally. Its principal product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as a vaccine adjuvant, and as a chemotherapy adjuvant for cancer patients with weakened immune systems. ZADAXIN has approval in approximately 30 countries, which include China, the Pacific Rim, Latin America, eastern Europe, and the Middle East. The company markets and sells ZADAXIN through distribution arrangements, local importers, and distributors. It also markets partnered products in China, including Depakine, an anti-convulsant; Tritace, an ACE inhibitor for the treatment of hypertension; Stilnox, a hypnotic for the short-term treatment of insomnia; and Aggrastat, a cardiology product. The company holds license, promotion, distribution, or marketing agreements for products, such as DC Bead, Loramyc, Abstral, and ondansetron RapidFilm, as well as Rapinyl. SciClone Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Foster City, California.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Ram Selvaraju Aegis Capital Buy   Mar 12, '14   4.59    Mar 12, '15  67.76% 
Raghuram Selvaraju Aegis Capital Buy   Nov 12, '13   4.79  8.00  Nov 12, '14  72.03% 
Ram Selvaraju Aegis Capital Buy   Nov 12, '13   4.79    Nov 12, '14  72.03% 
Raghuram Selvaraju Aegis Capital Buy   Sep 25, '13   5.18  9.00  Sep 25, '14  34.56% 
Ram Selvaraju Aegis Capital Buy   Sep 25, '13   5.18    Sep 25, '14  34.56% 
Raghuram Selvaraju Aegis Capital Buy   Jul 16, '13   5.95  9.00  Jul 16, '14  -18.32% 
Hamed Khorsand BWS Financial Buy   Sep 17, '12   4.69  8.25  Sep 17, '13  11.51%